Literature DB >> 9726695

Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy.

K Breithaupt-Grögler1, G Gerhardt, G Lehmann, T Notter, G G Belz.   

Abstract

The effects of 2 fixed antihypertensive combination drugs on blood pressure and aortic elastic properties were compared in 2 parallel groups. Twenty-six patients for 6 months received a calcium antagonist plus ACE inhibitor (verapamil SR 180 mg/trandolapril 1 mg (Vera/Tran)) and 25 patients a beta-adrenoceptor antagonist plus diuretic (metoprolol 100 mg/hydrochlorothiazide 12.5 mg (Meto/HCTZ)). In addition to blood pressure (SBP, DBP), carotidofemoral pulse wave velocity (PWV) was assessed non-invasively. Total peripheral resistance (TPR) was determined from cardiac output derived by electrical impedance cardiography. Sitting DBP decreased for -14.4 mmHg following Vera/Tran compared with -9.2 mmHg following Meto/HCTZ (p = 0.02 for difference between treatments). Blood pressure was normalized (i.e. DBP < 90 mmHg) in 69% of patients with Vera/Tran and in 52% with Meto/HCTZ. PWV was lowered with Vera/Tran to a higher extent than with Meto/HCTZ (differences between group means -0.46 to -0.98 m/sec, statistically not significant). Vera/Tran induced a decrease in TPR of about 15% of baseline values, whereas Meto/HCTZ showed no influence. Treatment-related adverse events following Meto/HCTZ were bradycardia and associated symptoms; following Vera/Tran these were cough and edema in 1 case each. In the Meto/HCTZ group, there were more withdrawals/drop-outs (9/25) than in the Vera/Tran group (2/26). The somewhat more intense reduction in PWV with Vera/Tran is indicative of an increase in aortic elastic properties associated with the more potent decrease in BP. In the present study, the combination of calcium antagonist plus ACE inhibitor was found to be an effective and well tolerated antihypertensive regimen and in these respects appears to have some advantages compared with a combination of beta-blocker plus diuretic.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726695

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  7 in total

Review 1.  Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure.

Authors:  J E Scoble
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

Review 2.  Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.

Authors:  Neil A Reynolds; Antona J Wagstaff; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Authors:  Richard B R Muijsers; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Fixed combination verapamil SR/trandolapril.

Authors:  M Dooley; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

5.  Combination therapy in hypertension: An update.

Authors:  Sanjay Kalra; Bharti Kalra; Navneet Agrawal
Journal:  Diabetol Metab Syndr       Date:  2010-06-24       Impact factor: 3.320

Review 6.  Using fixed-dose combination therapies to achieve blood pressure goals.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 7.  Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.

Authors:  Sanjib Kumar Sharma; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.